Oryzon Genomics SA Sustainability Reports

Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company and a leader in the development of epigenetics-based therapeutics. The company focuses on personalized medicine approaches for oncology, hematology, and central nervous system disorders.

Sector: Manufacturing

Country: Spain

Exchange: Bolsa de Madrid (BME)

LEI: 95980063R15RDF29DK13

FIGI: BBG001T2Z583

32 reports from 2014 to 2025

• Oryzon Genomics SA 2025 Annual Accounts and Management Report with Independent Audit Report
• Oryzon Genomics SA 2025 Environmental and Social Policy Report
• Oryzon Genomics SA 2025 Annual Corporate Governance Report of Listed Companies
• Oryzon Genomics SA 2024 Annual Accounts and Management Report with Independent Auditor's Report
• Oryzon Genomics SA 2024 Environmental and Social Policy Report